Higher mortality among lean patients with non‐alcoholic fatty liver disease despite fewer metabolic comorbidities
Alimentary Pharmacology & Therapeutics · 2023-05 · 57 (9) · 1014-1027
DOI: 10.1111/apt.17424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 23.02.2023. Verfasst von Karn Wijarnpreecha und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Cardiovascular Diseases. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, American Association for the Study of Liver Diseases, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Background & Aims Non‐alcoholic fatty liver disease (NAFLD) can develop in individuals who are not overweight. Whether lean persons with NAFLD have lower mortality and lower incidence of cirrhosis, cardiovascular diseases (CVD), diabetes mellitus (DM) and cancer than overweight/obese persons with NAFLD remains inconclusive. We compared mortality and incidence of cirrhosis, CVD, DM and cancer between lean versus non‐lean persons with NAFLD.
Methods
This is a retrospective study of adults with NAFLD in a single centre from 2012 to 2021. Primary outcomes were mortality and new diagnosis of cirrhosis, CVD, DM and cancer. Outcomes were modelled using competing risk analysis and Cox proportional hazards regression analysis.
Results
A total of 18,594 and 13,420 patients were identified for cross‐sectional and longitudinal analysis respectively: approximately 11% lean, 25% overweight, 28% class 1 obesity and 35% class 2–3 obesity. The median age was 51.0 years, 54.6% were women. The median follow‐up was 49.3 months. Lean patients had lower prevalence of metabolic diseases at baseline and lower incidence of cirrhosis and DM than non‐lean patients and no difference in CVD, any cancer or obesity‐related cancer during follow‐up. However, lean patients had significantly higher mortality with incidence per 1000 person‐years of 16.67, 10.11, 7.37 and 8.99, respectively, in lean, overweight, obesity class 1 and obesity class 2–3 groups respectively.
Conclusions
Lean patients with NAFLD had higher mortality despite lower incidence of cirrhosis and DM, and similar incidence of CVD and cancer and merit similar if not more attention as non‐lean patients with NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, Arizona, USA.
- School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
- School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
- Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA.
ORCID-Profile: Karn Wijarnpreecha, Fang Li, Sori K Lundin, Cui Tao, Vincent L Chen, Anna S F Lok
Förderung
- NIDDK NIH HHS
- American Association for the Study of Liver Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Wijarnpreecha, K., Li, F., Lundin, S. K., Suresh, D., Song, M. W., Tao, C., Chen, V. L., & Lok, A. S. F. (2023). Higher mortality among lean patients with non‐alcoholic fatty liver disease despite fewer metabolic comorbidities. Alimentary Pharmacology & Therapeutics, 57(9), 1014-1027. https://doi.org/10.1111/apt.17424
Vancouver
Wijarnpreecha K, Li F, Lundin SK, Suresh D, Song MW, Tao C, et al. Higher mortality among lean patients with non‐alcoholic fatty liver disease despite fewer metabolic comorbidities. Alimentary Pharmacology & Therapeutics. 2023;57(9):1014-1027. doi:10.1111/apt.17424
BibTeX
@article{Wijarnpreecha2023,
author = {Wijarnpreecha, Karn and Li, Fang and Lundin, Sori K and Suresh, Deepika and Song, Michael W and Tao, Cui and Chen, Vincent L and Lok, Anna S F},
title = {Higher mortality among lean patients with non‐alcoholic fatty liver disease despite fewer metabolic comorbidities},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
volume = {57},
number = {9},
pages = {1014--1027},
doi = {10.1111/apt.17424}
}
EUVIMED